Burden of community-acquired pneumonia in North American adults

Postgraduate Medicine

Volumn 122, Issue 2, 2010, Pages 130-141

  File Jr , Thomas M ^a   Marrie, Thomas J ^b  

^a Northeastern Ohio Medical University   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Adult; Community acquired pneumonia; Health care burden; Infectious diseases; North America; Prevention

Indexed keywords

ERYTHROMYCIN; MACROLIDE; METICILLIN; PENICILLIN G; PNEUMOCOCCUS VACCINE;

ACUTE CORONARY SYNDROME; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; COMMUNITY ACQUIRED PNEUMONIA; ECONOMIC ASPECT; EMPYEMA; HEALTH CARE COST; HEART FAILURE; HOSPITAL INFECTION; HOSPITAL READMISSION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; MORBIDITY; MORTALITY; NONHUMAN; NORTH AMERICA; PATHOPHYSIOLOGY; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; COST OF ILLNESS; ECONOMICS; HEALTH SURVEY; HOSPITALIZATION; MICROBIOLOGY; RISK FACTOR; STATISTICS;

ADULT; COMMUNITY-ACQUIRED INFECTIONS; COST OF ILLNESS; HEALTH CARE COSTS; HEALTH STATUS INDICATORS; HOSPITALIZATION; HUMANS; INCIDENCE; LENGTH OF STAY; NORTH AMERICA; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 77950344427     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.03.2130     Document Type: Review

References (112)

1. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31(2):347-382.
2. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
3. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis. 2000;31(2):383-421.
4. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-8):1-25.
5. Advisory Committee on Immunization Practices (ACIP). ACIP provisional recommendations for use of pneumococcal vaccines. 2008.
6. Atkinson W, Hamborsky J, McIntyre L, Wolfe C, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 10th ed. Washington, DC: Centers for Disease Control and Prevention; 2008.
7. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008(1):CD000422.
8. Whitney CG, Pilishvili T, Farley MM, et al. Long-term effect of 7-valent pneumococcal conjugate vaccine (PCV7) use on invasive pneumococcal disease (IPD) in the U.S. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC: October 25-28, 2008.
9. Metlay JP, Fishman NO, Joffe M, Edelstein PH. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine. 2006;24(4):468-475.
10. European Medicines Agency. Assessment report for Synflorix. 2009.
11. Scott DA, Komjathy SF, Hu BT, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2007;25(33):6164-6166.
12. Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28(4 suppl):S66-S76.
13. Christensen KL, Holman RC, Steiner CA, Sejvar JJ, Stoll BJ, Schonberger LB. Infectious disease hospitalizations in the United States. Clin Infect Dis. 2009;49(7):1025-1035.
14. DeFrances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National Hospital Discharge Survey. Natl Health Stat Rep. 2008;5:1-20.
15. National Center for Health Statistics. Health, United States, 2008: With special feature on the health of young adults. Hyattsville, MD: NCHS; 2009.
16. Canadian Institute for Health Information. Health Indicator Reports. Pneumonia and influenza hospitalization. http://www.cihi.ca/hireports/SearchServlet. Accessed April 28, 2009.
17. Marrie TJ, Shariatzadeh MR. Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore). 2007;86(2):103-111.
18. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2008;133(3):610-617.
19. Mortensen EM, Cornell J, Whittle J. Racial variations in processes of care for patients with community-acquired pneumonia. BMC Health Serv Res. 2004;4(1):20.
20. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with communityacquired pneumonia. Respir Res. 2005;6:82.
21. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest. 2007;131(2):466-473.
22. Mundy LM, Leet TL, Darst K, Schnitzler MA, Dunagan WC. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest. 2003;124(3):883-889.
23. Davydov L, Ebert SC, Restino M, et al. Prospective evaluation of the treatment and outcome of community-acquired pneumonia according to the Pneumonia Severity Index in VHA hospitals. Diagn Microbiol Infect Dis. 2006;54(4):267-275.
24. Malone DC, Shaban HM. Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia. Ann Pharmacother. 2001;35(10):1180-1185.
25. McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care. 2005;28(4):810-815.
26. Johnstone J, Eurich DT, Majumdar SR, Jin Y, Marrie TJ. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore). 2008;87(6):329-334.
27. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164(6):637-644.
28. Chokshi R, Restrepo MI, Weeratunge N, Frei CR, Anzueto A, Mortensen EM. Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2007;26(7):447-451.
29. Huang JQ, Hooper PM, Marrie TJ. Factors associated with length of stay in hospital for suspected community-acquired pneumonia. Can Respir J. 2006;13(6):317-324.
30. El Solh AA, Brewer T, Okada M, Bashir O, Gough M. Indicators of recurrent hospitalization for pneumonia in the elderly. J Am Geriatr Soc. 2004;52(12):2010-2015.
31. Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for rehospitalization of patients hospitalized with communityacquired pneumonia. Clin Infect Dis. 2008;46(4):550-556.
32. Quasney MW, Waterer GW, Dahmer MK, et al. Association between surfactant protein B ss1580 polymorphism and the risk of respiratory failure in adults with community-acquired pneumonia. Crit Care Med. 2004;32(5):1115-1119.
33. Waterer GW, ElBahlawan L, Quasney MW, Zhang Q, Kessler LA, Wunderink RG. Heat shock protein 70-2W1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. Crit Care Med. 2003;31(5):1367-1372.
34. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2006. Natl Health Stat Rep. 2008;8:1-29.
35. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39(11):1642-1650.
36. Jin Y, Carriere KC, Predy G, Johnson DH, Marrie TJ. The association between influenza immunization coverage rates and hospitalization for community-acquired pneumonia in Alberta. Can J Public Health. 2003;94(5):341-345.
37. Marrie TJ, Huang JQ. Epidemiology of community-acquired pneumonia in Edmonton, Alberta: an emergency department-based study. Can Respir J. 2005;12(3):139-142.
38. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250.
39. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of communityacquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA. 2000;283(6):749-755.
40. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56(10):1-120.
41. National Center for Health Statistics. GMWK290R: Death rates for 113 selected causes by 10-year age groups, race, and sex: United States,1999-2004. http://www.cdc.gov/nchs/datawh/statab/unpubd/mortabs/gmwk290_10.htm. Accessed June 15, 2009.
42. Statistics Canada. Age-standardized mortality rates by causes, by sex (Both sexes). http://www40.statcan.gc.ca/101/cst01/health30apeng.htm?sdihpneumonia. Accessed March 25, 2009.
43. Statistics Canada. Leading causes of death: 2000-2004. http://www.statcan.gc.ca/daily-quotidien/081204/dq081204c-eng.htm. Accessed March 25, 2009.
44. Lentino JR, Krasnicka B. Association between initial empirical therapy and decreased length of stay among veteran patients hospitalized with community acquired pneumonia. Int J Antimicrob Agents. 2002;19(1):61-66.
45. Feldman RB, Rhew DC, Wong JY, Charles RA, Goetz MB; American Thoracic Society. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital. Arch Intern Med. 2003;163(14):1718-1726.
46. Fine MJ, Stone RA, Lave JR, et al. Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial. Am J Med. 2003;115(5):343-351.
47. Halm EA, Horowitz C, Silver A, et al. Limited impact of a multicenter intervention to improve the quality and efficiency of pneumonia care. Chest. 2004;126(1):100-107.
48. Hauck LD, Adler LM, Mulla ZD. Clinical pathway care improves outcomes among patients hospitalized for community-acquired pneumonia. Ann Epidemiol. 2004;14(9):669-675.
49. Marras TK, Jamieson L, Chan CK. Inpatient care of communityacquired pneumonia: the effect of antimicrobial guidelines on clinical outcomes and drug costs in Canadian teaching hospitals. Can Respir J. 2004;11(2):131-137.
50. Stone RA, Mor MK, Lave JR, Hough LJ, Fine MJ. Implementation of an inpatient management and discharge strategy for patients with communityacquired pneumonia. Am J Manag Care. 2005;11(8):491-499.
51. Flanders SA, Dudas V, Kerr K, McCulloch CE, Gonzales R. Effectiveness of ceftriaxone plus doxycycline in the treatment of patients hospitalized with community-acquired pneumonia. J Hosp Med. 2006;1(1):7-12.
52. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333(7576):999.
53. Nathan RV, Rhew DC, Murray C, Bratzler DW, Houck PM, Weingarten SR. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med. 2006;119(6):512. e1-e7.
54. Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of betalactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2007;51(11):3977-3982.
55. Spaude KA, Abrutyn E, Kirchner C, Kim A, Daley J, Fisman DN. Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. Arch Intern Med. 2007;167(1):53-59.
56. Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in patients with pneumonia outside "flu" season: pleiotropic benefits or residual confounding? Am J Respir Crit Care Med. 2008;178(5):527-533.
57. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J. 2008;31(3):611-617.
58. Bodí M, Rodríguez A, Solé-Violán J, et al; Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis. 2005;41(12):1709-1716.
59. Yealy DM, Auble TE, Stone RA, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med. 2005;143(12):881-894.
60. Marrie TJ, Huang JQ. Low-risk patients admitted with communityacquired pneumonia. Am J Med. 2005;118(12):1357-1363.
61. Malcolm C, Marrie TJ. Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. Arch Intern Med. 2003;163(7):797-802.
62. Aliyu ZY, Aliyu MH, McCormick K. Determinants for hospitalization in "low-risk" community acquired pneumonia. BMC Infect Dis. 2003;3:11.
63. Rowe BH, Campbell SG, Boudreaux ED, et al. Community-acquired pneumonia in North American emergency departments: drug resistance and treatment success with clarithromycin. Acad Emerg Med. 2007;14(7):607-615.
64. Rifkin WD, Burger A, Holmboe ES, Sturdevant B. Comparison of hospitalists and nonhospitalists regarding core measures of pneumonia care. Am J Manag Care. 2007;13(3):129-132.
65. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360(14):1418-1428.
66. Pfaller MA, Ehrhardt AF, Jones RN. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. Am J Med. 2001;111(suppl 9A):4S-12S.
67. Ramanujam P, Rathlev NK. Blood cultures do not change management in hospitalized patients with community-acquired pneumonia. Acad Emerg Med. 2006;13(7):740-745.
68. Basi SK, Marrie TJ, Huang JQ, Majumdar SR. Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. Am J Med. 2004;117(5):305-311.
69. Centers for Disease Control and Prevention (CDC). Severe methicillinresistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep. 2007;56(14):325-329.
70. Adam H, McGeer A, Simor A. Fatal case of post-influenza, communityassociated MRSA pneumonia in an Ontario teenager with subsequent familial transmission. Can Commun Dis Rep. 2007;33(4):45-48.
71. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest. 2008;134(6):1141-1148.
72. Parmar MS. Paradise-not without its plagues: overwhelming Blastomycosis pneumonia after visit to lakeside cottages in Northeastern Ontario. BMC Infect Dis. 2005;5(1):30.
73. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network: Streptococcus pneumoniae, 1998. Atlanta, GA: Centers for Disease Control and Prevention; 1998.
74. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network: Streptococcus pneumoniae, 2001. Atlanta, GA: Centers for Disease Control and Prevention; 2001.
75. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network: Streptococcus pneumoniae, 2004. Atlanta, GA: Centers for Disease Control and Prevention; 2004.
76. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network: Streptococcus pneumoniae, 2007. Atlanta, GA: Centers for Disease Control and Prevention; 2007.
77. Sun HK, Nicolau DP, Kuti JL. Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae. Chest. 2006;130(3):807-814.
78. Metlay JP, Branas CC, Fishman NO. Hospital-reported pneumococcal susceptibility to penicillin. Emerg Infect Dis. 2004;10(1):54-59.
79. Centers for Disease Control and Prevention. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae-United States, 2006-2007. MMWR Morb Mortal Wkly Rep. 2008;57(50):1353-1355.
80. Palmer CS, Zhan C, Elixhauser A, et al. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clin Ther. 2000;22(2):250-264.
81. Orrick JJ, Segal R, Johns TE, Russell W, Wang F, Yin DD. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to Infectious Diseases Society of America guidelines. Pharmacoeconomics. 2004;22(11):751-757.
82. Asche C, McAdam-Marx C, Seal B, Crookston B, Mullins CD. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. J Antimicrob Chemother. 2008;61(5):1162-1168.
83. Ye X, Sikirica V, Schein JR, et al. Treatment failure rates and health care utilization and costs among patients with communityacquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin Ther. 2008;30(2):358-371.
84. Thomsen RW, Riis A, Nørgaard M, et al. Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Denmark. J Intern Med. 2006;259(4):410-417.
85. Trotter CL, Stuart JM, George R, Miller E. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis. 2008;14(5):727-733.
86. Gentile JH, Sparo MD, Mercapide ME, Luna CM. Adult bacteremic pneumococcal pneumonia acquired in the community. A prospective study on 101 patients. Medicina (B Aires). 2003;63(1):9-14.
87. Almirall J, Bolíbar I, Vidal J, et al. Epidemiology of communityacquired pneumonia in adults: a population-based study. Eur Respir J. 2000;15(4):757-763.
88. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA. 2005;294(21):2712-2719.
89. Administration on Aging. A profile of older Americans: 2007. Washington, DC: US Dept of Health and Human Services, Administration on Aging; 2008.
90. Selvin E, Coresh J, Brancati FL. The burden and treatment of diabetes in elderly individuals in the U.S. Diabetes Care. 2006;29(11):2415-2419.
91. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schønheyder HC, Sørensen HT. Type 2 diabetes and pneumonia outcomes: a populationbased cohort study. Diabetes Care. 2007;30(9):2251-2257.
92. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schønheyder HC, Sørensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31(8):1541-1545.
93. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596-615.
94. National Institutes of Health. Morbidity and mortality: 2007 chart book on cardiovascular, lung, and blood diseases. Washington, DC: National Heart, Lung, and Blood Institute; 2007.
95. Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the economic burden of COPD in the US: a review and synthesis of the literature. COPD. 2006;3(4):211-218.
96. Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med. 2000;94(3):204-213.
97. Leigh JP, Romano PS, Schenker MB, Kreiss K. Costs of occupational COPD and asthma. Chest. 2002;121(1):264-272.
98. Dean NC, Bateman KA, Donnelly SM, Silver MP, Snow GL, Hale D. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest. 2006;130(3):794-799.
99. Menendez R, Torres A. Treatment failure in community-acquired pneumonia. Chest. 2007;132(4):1348-1355.
100. Switzer GE, Halm EA, Chang CC, Mittman BS, Walsh MB, Fine MJ. Physician awareness and self-reported use of local and national guidelines for community-acquired pneumonia. J Gen Intern Med. 2003;18(10):816-823.
101. Wu JH, Howard DH, McGowan JE Jr, Turpin RS, Henry Hu X. Adherence to Infectious Diseases Society of America guidelines for empiric therapy for patients with community-acquired pneumonia in a commercially insured cohort. Clin Ther. 2006;28(9):1451-1461.
102. Kumar S, Wang L, Fan J, et al. Detection of 11 common viral and bacterial pathogens causing community-acquired pneumonia or sepsis in asymptomatic patients by using a multiplex reverse transcription-PCR assay with manual (enzyme hybridization) or automated (electronic microarray) detection. J Clin Microbiol. 2008;46(9):3063-3072.
103. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med. 2002;76(1):105-115.
104. Brundage JF, Shanks GD. Deaths from bacterial pneumonia during1918-19 influenza pandemic. Emerg Infect Dis. 2008;14(8):1193-1199.
105. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180(1):48-58.
106. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec. 2007;12(82):93-104.
107. Nichol KL, Zimmerman R. Generalist and subspecialist physicians' knowledge, attitudes, and practices regarding influenza and pneumococcal vaccinations for elderly and other high-risk patients: a nationwide survey. Arch Intern Med. 2001;161(22):2702-2708.
108. Nichol KL, MacDonald R, Hauge M. Factors associated with influenza and pneumococcal vaccination behavior among high-risk adults. J Gen Intern Med. 1996;11(11):673-677.
109. Zimmerman RK, Tabbarah M, Nowalk MP, et al. Predictors of pneumococcal polysaccharide vaccination among patients at three inner-city neighborhood health centers. Am J Geriatr Pharmacother. 2005;3(3):149-159.
110. Centers for Disease Control (CDC). Adult immunization: knowledge, attitudes, and practices-DeKalb and Fulton Counties, Georgia, 1988. MMWR Morb Mortal Wkly Rep. 1988;37(43):657-661.
111. Centers for Disease Control and Prevention (CDC). Reasons reported by Medicare beneficiaries for not receiving influenza and pneumococcal vaccinations-United States, 1996. MMWR Morb Mortal Wkly Rep. 1999;48(39):886-890.
112. Ridda I, Lindley IR, Gao Z, McIntyre P, MacIntyre CR. Differences in attitudes, beliefs and knowledge of hospital health care workers and community doctors to vaccination of older people. Vaccine. 2008;26(44):5633-5640.